ArticleFrontiers in pharmacology2022

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Ye Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.